
ENABLING TARGETED SUCCESS
ENABLING TARGETED SUCCESS

Nanocarriers
The benefits of encapsulating an active compound into nanocarriers (NCs) are:
- Life cycle management: NC delivery can change the biodistribution and pharmacokinetic of the therapeutic cargos so that differentiating features, e.g long drug circulating time, slow drug release or cell specific drug delivery are achieved.
- Rescuing pipeline failures: NC delivery can provide effects that improve therapeutic efficacy. Furthermore, NC can protect the in vivo environment from harmful drugs (off target effects) and reduce toxicity.
- Enabling novel therapies: NC protect their therapeutic cargo from the in vivo environment, which can improve the stability of the drug and enhance its target engagement (on target).
- New indications: NC delivered drugs could be proposed for new indications.
NANOMEDICINES
Nanomedicine refers to the medical application of nanotechnology. Among others, one research area of nanomedicine deals with the development of drug delivery systems for therapeutic agents using nanoparticles with diameters between 1-1000 nm. These nanoparticles are designed to improve the bioavailability and pharmacokinetics of therapeutics and to provide the possibility of delivering the drugs to specific cells or tissues. Lipid-based nanoparticles are most commonly used. Their modular structure (lipid composition, payload, and targeting ligands) enable a customized adaption of properties resulting in specific nanocarriers for a variety of diseases.

Nanoparticle

Drug playload

Targeting ligands on the surface

Customised Nanocarrier / Nanomedicine
CDMO
Fast results without high investment costs
An assessment of the ability to develop at the earliest stages of drug development can speed up candidate selection and ease go/no-go decisions
TargoSphere


- Proprietary compounds that Rodos receives from partners in licensing and co-development transactions for the purpose of enabling innovative treatments
- Proprietary compounds that dropped out from the pipeline of pharmaceutical companies in the phase I or phase II clinical stage due to severe side effects. Formulating of these APIs with nanocarriers may improve the therapeutic window and to rescue these drugs for the partners
- Generic or close to off-patent compounds that are reformulated into nanocarriers for the purpose of providing novel and unique properties of treatment
INVESTORS
NEWS
Fresh Capital for Nanomedicine Development against Chronic Inflammatory Autoimmune Diseases
Rodos receives 2019 Business Excellence Award
Seedmatch-Investor steigt bei Rodos Biotarget groß ein
Just rewards: Crowdfunding for German VC-backed startups
Biotechnologiereport 2017 – „Spot on Innovation“
Marcus Furch sprach mit dem Bundesminister für Gesundheit Herman Gröhe.
Rodos Biotarget GmbH selected as a finalist for Red Herring’s Top 100 Europe award.
Rodos Biotarget GmbH announced today it has been selected as a finalist for Red Herring’s Top 100 Europe award.
Biotechnologiereport 2017 „Spot on Innovation“
Rodos Biotarget GmbH 2017 Business Excellence Awards Biopharmaceutical Firm of the Year
GET IN TOUCH

Rodos BioTarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 31
30625 Hannover / Germany
Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837
E-Mail: info@biotargeting.eu
www.biotargeting.eu
Potsdam Science Park
Am Mühlenberg 11
14476 Potsdam / Germany
Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837
E-Mail: info@biotargeting.eu
www.biotargeting.eu